NbN3 vs SIRS 2025
Price, ratings, monetisation and update history for both apps, side by side — with what reviewers say about each.
NbN3
This app provides a neuroscience-based nomenclature for psychotropic medications, reflecting current knowledge and aiding clinicians in making informed prescription decisions. It includes detailed information on pharmacology, mode of action, indications, efficacy, side effects, practical notes, and neurobiology.
- Neuroscience-based nomenclature
- Pharmacology and mode of action
- Approved indications
- Efficacy and side effects
- Practical clinical notes
- Neurobiology details
- Links to IUPHAR
Read full descriptionHide full description
It has become clear that the current pharmacological nomenclature of psychotropic medications does not reflect our contemporary knowledge, nor does it inform properly the clinician of neuroscience-based prescriptions. Very often we prescribe “antidepressants” for “anxiety” disorders or “second-generation antipsychotics” to depressed patients. This practice is confusing. • Five international organizations ECNP, ACNP, AsCNP, CINP & IUPHAR decided five years ago to establish a taskforce and gave it the mission to embed our current neuroscience advances in the nomenclature. • The scope is to include all the medications with CNS indications and to harness this new nomenclature to help clinicians when they are trying to figure out what would be the next rational “neuropsychopharmacological step”. • In this second edition 22 new medications were added so NbN includes now 130 medications. This proposed nomenclature aims to reflect the current pharmacological knowledge base and cannot necessarily represent the ultimate scientific truth. The taskforce that assembled could have taken the stand that our current knowledge base is not enough to define the primary target or the correct mechanisms of action. But as a taskforce, we feel that it’s better to present a cutting-edge scientific interpretation than to wait for the definitive conclusion. We need to treat our patients now, and we cannot postpone treatment until all the facts are known. Therefore this nomenclature is based on: 1. The need to treat now. 2. Updated neuroscience insights. 3. The judgment of the members of the taskforce. Along these lines, we have come up with the following proposal: The Nomenclature: Pharmacology and Mode of Action – reflects the current knowledge and understanding about the targeted neurotransmitter/ molecule/system being modified and the mode/mechanism of action. We also added 4 additional dimensions 4 Additional Dimensions: Approved Indications – based on the recommendations of major regulatory bodies (e.g. FDA, EMA, etc.) Efficacy and Side Effects – Driven from positive single, large, RCT and/or “heavy solid weight” clinical data. Only prevalent or life-threatening side effects were included Practical Note – Summarizes the clinical knowledge that has been "filtered" through the taskforce's "sieve" Neurobiology – This dimension is focused on the biology. It is divided into preclinical and clinical sections, with the emphasis on the latter For those who would like to know more abo derived from empirical data.ut the pharmacology, there is a direct link to the relevant site of IUPHAR – our collaborator in this endeavour. As this is on-going process, we recognize that the product is imperfect. Based on your feedback (and taking into account the feedback of other colleges) new reports and findings, appropriate updates (e.g. later editions) will be undertaken.
SIRS 2025
This app serves as a global platform for researchers and clinicians focused on schizophrenia and related disorders. It aims to foster collaboration and knowledge sharing within the scientific community.
- Connect researchers and clinicians
- Focus on schizophrenia and related disorders
- Facilitate worldwide collaboration
- Share scientific knowledge
Read full descriptionHide full description
Welcome to the Schizophrenia International Research Society. The mission of the Schizophrenia International Research Society (SIRS) is to be a worldwide organization that aims to bring together researchers and clinicians in schizophrenia and related disorders.
Screenshots
Verdict
The clearest difference is rating: NbN3 at 4.1 against SIRS 2025's 1.0. NbN3 also leads on review sentiment (40% vs 0%) and ratings volume (7 vs 1). SIRS 2025's advantage is update cadence (every 2 weeks vs every 2 months). On price, ads, in-app purchases and monetization model there is nothing between them.
Scored on Price · Rating · Positive reviews · Number of ratings · Update frequency · Ads · In-app purchases · Monetization · Best chart rank · Devices · Requires iOS
Both are free to download. Neither carries in-app purchases, so what you see is what you pay.
NbN3 holds the better App Store score, 4.1 against 1.0. That said, the two scores are not equally well evidenced: NbN3 has 7 ratings behind it against 1, so its average is the more settled of the two. Written reviews point the same way: 40% of NbN3's written reviews are positive against 0% of SIRS 2025's.
NbN3 ships an update every 2 months, SIRS 2025 every 2 weeks. Both last shipped on November 19, 2026.
| Parameter | NbN3 | SIRS 2025 |
|---|---|---|
| Price | Free | Free |
| Rating | 4.1 (7 ratings) — better | 1.0 (1 ratings) |
| Positive reviews | 40.0% of reviews — better | 0.0% of reviews |
| Number of ratings | 7 — better | 1 |
| Update frequency | Every 2 months | Every 2 weeks — better |
| Ads | No | No |
| In-app purchases | No | No |
| Monetization | Free | Free |
| Devices | iPhone, iPod | iPhone, iPad, iPod — better |
| Requires iOS | 15.1 — better | 15.6 |
| Further details — not scored | ||
| Size | 24 MB | 85 MB |
| Age rating | 17+ | 4+ |
| Developer | European College of Neuropsychopharmacology (ECNP) | THANIGAIVELAN MUTHU |
Customer experience
NbN3
SIRS 2025
In-app purchases
NbN3
No in-app purchases
SIRS 2025
No in-app purchases
Questions
Is NbN3 free?
Is SIRS 2025 free?
Which has better reviews, NbN3 or SIRS 2025?
Do NbN3 or SIRS 2025 have ads?
Which is updated more often, NbN3 or SIRS 2025?
Other comparisons















